Bicycle Therapeutics (STU:50BA) 3-Year Revenue Growth Rate : 11.80% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics 3-Year Revenue Growth Rate?

Bicycle Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was €0.42.

During the past 12 months, Bicycle Therapeutics's average Revenue per Share Growth Rate was 110.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was -3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 7 years, the highest 3-Year average Revenue per Share Growth Rate of Bicycle Therapeutics was 51.90% per year. The lowest was -26.90% per year. And the median was 3.65% per year.

Competitive Comparison of Bicycle Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Bicycle Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicycle Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's 3-Year Revenue Growth Rate falls into.

Bicycle Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Bicycle Therapeutics (STU:50BA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Bicycle Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicycle Therapeutics (STU:50BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (STU:50BA) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

BCYC:USA 50BA:Germany

Address

Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS

Website

https://www.bicycletherapeutics.com

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Bicycle Therapeutics (STU:50BA) Headlines

No Headlines